Try our corporate solution for free!
(212) 419-8286

Leading pharmaceutical companies and total global vaccine revenue 2017 and 2024

GlaxoSmithKline was the global leader based on revenues generated through vaccine products in 2017 and is forecasted to maintain this position up to 2024. The London-based pharmaceutical manufacturer generates around one fifth of its total revenue through the vaccines segment. GlaxoSmithKline’s vaccines, among others, target meningitis, influenza, shingles, and hepatitis. Other top players in the global vaccine business are Merck & Co., Sanofi, and Pfizer.

Vaccine market overview

The vaccine market worldwide is expected to increase with a compound annual growth rate of seven percent between 2017 and 2024. A main driver of the growth is the increase of various infectious diseases like influenza, swine flu, hepatitis, tuberculosis, diphtheria, Ebola, and meningococcal and pneumococcal diseases. The United States are the world’s largest national market for vaccines, while North America is, accordingly, the largest regional market, followed by Europe. Vaccines which are administered intramuscularly make up over half of global revenues, while vaccines which are administered subcutaneously make up around one fifth of the market. Pfizer’s Prevnar 13 is currently the world’s top vaccine product, generating around 5.7 billion U.S. dollars of revenue.

The impact of vaccines

  Originally, the main aim of vaccinations (immunizations) was to prevent infections from certain diseases and thus to reduce outbreaks and larger epidemics within the population. Thanks to vaccines, infectious diseases which once had high death rates like polio and smallpox have been nearly eradicated. Others, like measles, mumps, and whooping cough, are mostly under control. However, vaccines can also be used after an infection occurs as a therapeutic. Therapeutic vaccines in immuno-oncology are one of the latest big things in cancer treatment.

Top 10 pharmaceutical companies based on global vaccine revenues in 2017 and 2024

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until December 20th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

June 2018



Survey time period

as of May 2018

Supplementary notes

* Projected. Companies are ranked by 2024 revenues.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Vaccinations in the U.S."

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.